WO2009068708A3 - Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo - Google Patents

Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo Download PDF

Info

Publication number
WO2009068708A3
WO2009068708A3 PCT/ES2008/000731 ES2008000731W WO2009068708A3 WO 2009068708 A3 WO2009068708 A3 WO 2009068708A3 ES 2008000731 W ES2008000731 W ES 2008000731W WO 2009068708 A3 WO2009068708 A3 WO 2009068708A3
Authority
WO
WIPO (PCT)
Prior art keywords
somatostatin
pharmaceutical composition
analogue
prolonged release
diarrhoea
Prior art date
Application number
PCT/ES2008/000731
Other languages
English (en)
French (fr)
Other versions
WO2009068708A8 (es
WO2009068708A2 (es
Inventor
Duena Antonio Parente
Claudia Savulsky
Garces Josep Garces
Vizcaino Ricard Mis
Original Assignee
Gp Pharm Sa
Duena Antonio Parente
Claudia Savulsky
Garces Josep Garces
Vizcaino Ricard Mis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gp Pharm Sa, Duena Antonio Parente, Claudia Savulsky, Garces Josep Garces, Vizcaino Ricard Mis filed Critical Gp Pharm Sa
Priority to EP08855638A priority Critical patent/EP2223684B1/en
Priority to DK08855638.6T priority patent/DK2223684T3/da
Priority to PL08855638T priority patent/PL2223684T3/pl
Priority to US12/744,106 priority patent/US20110124563A1/en
Priority to ES08855638T priority patent/ES2414472T3/es
Priority to SI200830961T priority patent/SI2223684T1/sl
Publication of WO2009068708A2 publication Critical patent/WO2009068708A2/es
Publication of WO2009068708A3 publication Critical patent/WO2009068708A3/es
Publication of WO2009068708A8 publication Critical patent/WO2009068708A8/es
Priority to HRP20130447AT priority patent/HRP20130447T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composición farmacéutica de somatostatina, o un análogo de somatostatina, de liberación sostenida para su uso en el tratamiento y/o prevención de la diarrea y su uso en la preparación de un medicamento para el tratamiento y/o prevención de la diarrea.
PCT/ES2008/000731 2007-11-23 2008-11-21 Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo WO2009068708A2 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP08855638A EP2223684B1 (en) 2007-11-23 2008-11-21 Pharmaceutical composition with prolonged release of octreotide acetate
DK08855638.6T DK2223684T3 (da) 2007-11-23 2008-11-21 Farmaceutisk sammensætning med langvarig frigivelse af octreotidacetat
PL08855638T PL2223684T3 (pl) 2007-11-23 2008-11-21 Kompozycja farmaceutyczna o przedłużonym uwalnianiu octanu oktreotydu
US12/744,106 US20110124563A1 (en) 2007-11-23 2008-11-21 Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
ES08855638T ES2414472T3 (es) 2007-11-23 2008-11-21 Composición farmacéutica de liberación sostenida de acetato de octreotide
SI200830961T SI2223684T1 (sl) 2007-11-23 2008-11-21 Farmacevtski sestavek s podaljšanim sproščanjem oktreotidnega acetata
HRP20130447AT HRP20130447T1 (en) 2007-11-23 2013-05-22 Pharmaceutical composition with prolonged release of octreotide acetate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200703103 2007-11-23
ES200703103A ES2324009B1 (es) 2007-11-23 2007-11-23 Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.

Publications (3)

Publication Number Publication Date
WO2009068708A2 WO2009068708A2 (es) 2009-06-04
WO2009068708A3 true WO2009068708A3 (es) 2009-07-16
WO2009068708A8 WO2009068708A8 (es) 2010-10-21

Family

ID=40589822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2008/000731 WO2009068708A2 (es) 2007-11-23 2008-11-21 Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo

Country Status (13)

Country Link
US (1) US20110124563A1 (es)
EP (1) EP2223684B1 (es)
AR (1) AR069420A1 (es)
CL (1) CL2008003489A1 (es)
CY (1) CY1114045T1 (es)
DK (1) DK2223684T3 (es)
ES (2) ES2324009B1 (es)
HR (1) HRP20130447T1 (es)
PL (1) PL2223684T3 (es)
PT (1) PT2223684E (es)
SI (1) SI2223684T1 (es)
TW (1) TWI463991B (es)
WO (1) WO2009068708A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116942677A (zh) 2015-09-21 2023-10-27 梯瓦制药国际有限责任公司 缓释奥氮平制剂
US10980882B2 (en) * 2015-09-25 2021-04-20 Jennifer J. KANG-MIELER Biodegradable microsphere-hydrogel ocular drug delivery system
US11266608B2 (en) 2015-09-25 2022-03-08 Jennifer J. Kang-Mteler Biodegradable extended release microsphere-hydrogel ocular drug delivery system and method
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
US11801217B2 (en) 2017-07-17 2023-10-31 Medincell S.A. Biodegradable block copolymer drug delivery composition
FR3079421A1 (fr) * 2018-03-28 2019-10-04 Edix Sa Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
AU2022308198A1 (en) 2021-07-06 2024-02-01 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
WO2023092148A1 (en) * 2021-11-22 2023-05-25 SpecGx LLC Injectable sustained release pharmaceutical composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026015A1 (en) * 1996-01-16 1997-07-24 Delab Sustained release drug formulations
EP1151746A1 (en) * 1999-12-17 2001-11-07 Lipotec, S.A. Microcapsules for sustained release of drugs
WO2004112752A1 (en) * 2003-06-26 2004-12-29 Peptron Co., Ltd Method of preparing mixed formulation of sustained release microspheres by continuous one-step process

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
SE9100610D0 (sv) * 1991-03-04 1991-03-04 Procordia Ortech Ab Bioresorbable material for medical use
US6214792B1 (en) * 1996-04-12 2001-04-10 David Lew Simon Method for treating acute and severe diarrhea
DE19621533A1 (de) * 1996-05-29 1997-12-04 Bosch Gmbh Robert Elektromotorische Bremsvorrichtung
US6150333A (en) * 1998-07-30 2000-11-21 Biomeasure, Inc. Methods of using a somatostatin analogue
BRPI0412059A (pt) * 2003-07-15 2006-09-05 Pr Pharmaceuticals Inc método para a preparação de formulação de liberação controlada
PT1968549E (pt) * 2005-12-22 2014-08-29 Novartis Ag Formulação de libertação controlada compreendendo octreotida e dois ou mais polímeros de polilactídeo-co-glicolídeo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026015A1 (en) * 1996-01-16 1997-07-24 Delab Sustained release drug formulations
EP1151746A1 (en) * 1999-12-17 2001-11-07 Lipotec, S.A. Microcapsules for sustained release of drugs
WO2004112752A1 (en) * 2003-06-26 2004-12-29 Peptron Co., Ltd Method of preparing mixed formulation of sustained release microspheres by continuous one-step process

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLANCO-PRETO M J ET AL: "In vitro and in vivo evaluation of a somatostatin analogue released from PLGA microspheres", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 67, no. 1, 1 June 2000 (2000-06-01), pages 19 - 28, XP004196069, ISSN: 0168-3659 *
YAVUZ MELEK N ET AL: "The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study.", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS 1 SEP 2002, vol. 54, no. 1, 1 September 2002 (2002-09-01), pages 195 - 202, XP002527245, ISSN: 0360-3016 *

Also Published As

Publication number Publication date
ES2324009B1 (es) 2010-05-21
EP2223684A2 (en) 2010-09-01
DK2223684T3 (da) 2013-06-17
ES2414472T3 (es) 2013-07-19
ES2324009A1 (es) 2009-07-28
PL2223684T3 (pl) 2013-08-30
CY1114045T1 (el) 2016-07-27
SI2223684T1 (sl) 2013-07-31
PT2223684E (pt) 2013-06-20
TW200936157A (en) 2009-09-01
CL2008003489A1 (es) 2009-05-29
EP2223684B1 (en) 2013-03-27
US20110124563A1 (en) 2011-05-26
HRP20130447T1 (en) 2013-06-30
WO2009068708A8 (es) 2010-10-21
TWI463991B (zh) 2014-12-11
AR069420A1 (es) 2010-01-20
WO2009068708A2 (es) 2009-06-04

Similar Documents

Publication Publication Date Title
WO2009068708A8 (es) Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
IL229304A (en) Compounds 1 ', 3' - Imaging Converts - 4 - Phenyl - 3, 4, 5, 6 - Tetrahydro - 2h, 1'h, [1, 4 '] Bipyridinyl - 2' - lozenges, pharmaceutical preparations containing them and their use
IL199835A (en) Acid-activated antimicrobial peptides, their pharmaceutical preparations, and their use in drug preparation
IL206789A (en) A converted cyclic amide compound, a pharmaceutical preparation containing the compound and the use of a compound or pharmaceutical preparation in a pharmaceutical preparation
IL206395A (en) N- Heterocyclic-7-Oxo-6-Sulphoxy-6,1-Diazabicyclo [1.2.3] Octane-2-Carboxamides and Pharmaceuticals Containing Them
EP1940361A4 (en) PHARMACEUTICAL DOSAGE FORMS HAVING CONTROLLED AND / OR IMMEDIATE RELEASE PROPERTIES
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2008128115A3 (en) Low-dose doxepin formulations
IL194699A (en) Tetrahydropridridines, preparations containing them and uses in the preparation of drugs
IL206808A (en) Indolyl-pyridone history, their pharmaceutical preparations and their uses
PL2083809T3 (pl) Kompozycja dietetyczna lub farmaceutyczna zawierająca tricykliczne diterpeny do leczenia depresji
WO2010021607A3 (en) Pharmaceutical formulation
EP2015740A4 (en) NEW LOW-DOSED PHARMACEUTICAL COMPOSITIONS WITH NIMESULID, PREPARATION AND USE
EP2261221A4 (en) EPOTHILONE ANALOGUES, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR USE AND PREPARATIONS
IL201730A (en) History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs
CL2008000303A1 (es) Compuestos derivados de 1-oxa-3-azaespiro[4.5]decan-2-ona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno de la alimentacion, obesidad, depresion.
TWI368521B (en) A spontaneous pharmaceutical composition for treatment and prevention of proliferative diseases,uses and preparation thereof
EP2208732A4 (en) DEHYDROXYLATED VANCOMYCIN, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
WO2008003050A3 (en) Gallium nitrate formulations
PL1742927T3 (pl) Pochodne kwasu butanowego, sposoby ich otrzymywania, kompozycje farmaceutyczne zawierające takie pochodne i terapeutyczne zastosowanie takich pochodnych
WO2010046061A3 (de) Kosmetische und/oder pharmazeutische zubereitungen

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008855638

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08855638

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12744106

Country of ref document: US